Suppr超能文献

通过靶向细胞分裂的多个途径优化巨核细胞多倍体化。

Optimizing megakaryocyte polyploidization by targeting multiple pathways of cytokinesis.

机构信息

Platelet Biology Laboratory, New York Blood Center, Lindsley F. Kimball Research Institute, New York, New York 10065, USA.

出版信息

Transfusion. 2012 Nov;52(11):2406-13. doi: 10.1111/j.1537-2995.2012.03711.x. Epub 2012 May 21.

Abstract

BACKGROUND

Large-scale in vitro production of platelets (PLTs) from cord blood stem cells is one goal of stem cell research. One step toward this goal will be to produce polyploid megakaryocytes capable of releasing high numbers of PLTs. Megakaryocyte polyploidization requires distinct cytoskeletal and cellular mechanisms, including actin polymerization, myosin activation, microtubule formation, and increased DNA production. In this study we variably combined inhibition of these principal mechanisms of cytokinesis with the goal of driving polyploidization in megakaryocytes.

STUDY DESIGN AND METHODS

Megakaryocytes were derived from umbilical cord blood and cultured with reagents that inhibit distinct mechanisms of cytokinesis: Rho-Rock inhibitor (RRI), Src inhibitor (SI), nicotinamide (NIC), aurora B inhibitor (ABI), and myosin light chain kinase inhibitor (MLCKI). Combinations of reagents were used to determine their interactions and to maximize megakaryocyte ploidy.

RESULTS

Treatment with RRI, NIC, SI, and ABI, but not with MLCKI, increased the final ploidy and RRI was the most effective single reagent. RRI and MLCKI, both inhibitors of MLC activation, resulted in opposite ploidy outcomes. Combinations of reagents also increased ploidy and the use of NIC, SI, and ABI was as effective as RRI alone. Addition of MLCKI to NIC, SI, and ABI reached the highest level of polyploidization.

CONCLUSION

Megakaryocyte polyploidization results from modulation of a combination of distinct cytokinesis pathways. Reagents targeting distinct cytoskeletal pathways produced additive effects in final megakaryocyte ploidy. The RRI, however, showed no additive effect but produced a high final ploidy due to overlapping inhibition of multiple cytokinesis pathways.

摘要

背景

从脐带血干细胞大规模生产血小板(PLTs)是干细胞研究的一个目标。实现这一目标的一个步骤将是产生能够释放大量 PLTs 的多倍体巨核细胞。巨核细胞的多倍体化需要独特的细胞骨架和细胞机制,包括肌动蛋白聚合、肌球蛋白激活、微管形成和增加 DNA 产生。在这项研究中,我们通过可变地组合抑制有丝分裂的这些主要机制,来驱动巨核细胞的多倍体化。

研究设计与方法

从脐带血中衍生巨核细胞,并在含有抑制有丝分裂不同机制的试剂中培养:Rho-ROCK 抑制剂(RRI)、Src 抑制剂(SI)、烟酰胺(NIC)、极光 B 抑制剂(ABI)和肌球蛋白轻链激酶抑制剂(MLCKI)。使用组合试剂来确定它们的相互作用并使巨核细胞的多倍体化最大化。

结果

用 RRI、NIC、SI 和 ABI 处理,但不是用 MLCKI 处理,增加了最终的多倍体,而 RRI 是最有效的单一试剂。RRI 和 MLCKI,都是肌球蛋白轻链激活的抑制剂,导致相反的多倍体结果。组合试剂也增加了多倍体,并且 NIC、SI 和 ABI 的使用与 RRI 单独使用一样有效。将 MLCKI 添加到 NIC、SI 和 ABI 中达到了最高的多倍体化水平。

结论

巨核细胞的多倍体化是通过调节一系列不同的有丝分裂途径而产生的。针对不同细胞骨架途径的试剂在最终巨核细胞的多倍体中产生了相加的效果。然而,RRI 没有相加的效果,但由于多个有丝分裂途径的重叠抑制,产生了很高的最终多倍体。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验